Balance Sheet
Cash Flow Statement
Amortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Gains from Investment Securities: 2018-2023

Historic Gains from Investment Securities for Legend Biotech (LEGN) over the last 5 years, with Dec 2023 value amounting to -$663,000.

  • Legend Biotech's Gains from Investment Securities rose 658.33% to $201,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $129,000, marking a year-over-year increase of 110.05%. This contributed to the annual value of -$663,000 for FY2023, which is 11.80% down from last year.
  • According to the latest figures from FY2023, Legend Biotech's Gains from Investment Securities is -$663,000, which was down 11.80% from -$593,000 recorded in FY2022.
  • Legend Biotech's 5-year Gains from Investment Securities high stood at -$47,000 for FY2020, and its period low was -$663,000 during FY2023.
  • Moreover, its 2-year median value for Gains from Investment Securities was -$628,000 (2022), whereas its average is -$628,000.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 432.58% in 2019, then soared by 90.08% in 2020.
  • Over the past 4 years, Legend Biotech's Gains from Investment Securities (Yearly) stood at -$474,000 in 2019, then soared by 90.08% to -$47,000 in 2020, then reached -$593,000 in 2022, then declined by 11.80% to -$663,000 in 2023.